Corrigendum to 'Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease' EBioMedicine 47 (2019) 446-456

LaTonya J Hickson; Larissa G P Langhi Prata; Shane A Bobart; Tamara K Evans; Nino Giorgadze; Shahrukh K Hashmi; Sandra M Herrmann; Michael D Jensen; Qingyi Jia; Kyra L Jordan; Todd A Kellogg; Sundeep Khosla; Daniel M Koerber; Anthony B Lagnado; Donna K Lawson; Nathan K LeBrasseur; Lilach O Lerman; Kathleen M McDonald; Travis J McKenzie; João F Passos; Robert J Pignolo; Tamar Pirtskhalava; Ishran M Saadiq; Kalli K Schaefer; Stephen C Textor; Stella G Victorelli; Tammie L Volkman; Ailing Xue; Mark A Wentworth; Erin O Wissler Gerdes; David B Allison; Stephanie L Dickinson; Keisuke Ejima; Elizabeth J Atkinson; Marc Lenburg; Yi Zhu; Tamara Tchkonia; James L Kirkland

doi:10.1016/j.ebiom.2019.12.004

Corrigendum to 'Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease' EBioMedicine 47 (2019) 446-456

EBioMedicine. 2020 Feb:52:102595. doi: 10.1016/j.ebiom.2019.12.004. Epub 2020 Jan 23.

Authors

LaTonya J Hickson¹, Larissa G P Langhi Prata², Shane A Bobart³, Tamara K Evans⁴, Nino Giorgadze², Shahrukh K Hashmi⁵, Sandra M Herrmann³, Michael D Jensen⁶, Qingyi Jia⁶, Kyra L Jordan³, Todd A Kellogg⁷, Sundeep Khosla⁸, Daniel M Koerber², Anthony B Lagnado⁹, Donna K Lawson¹⁰, Nathan K LeBrasseur¹¹, Lilach O Lerman³, Kathleen M McDonald¹², Travis J McKenzie⁷, João F Passos⁹, Robert J Pignolo¹³, Tamar Pirtskhalava², Ishran M Saadiq³, Kalli K Schaefer², Stephen C Textor³, Stella G Victorelli⁹, Tammie L Volkman⁴, Ailing Xue², Mark A Wentworth¹², Erin O Wissler Gerdes⁴, David B Allison¹⁴, Stephanie L Dickinson¹⁴, Keisuke Ejima¹⁴, Elizabeth J Atkinson¹⁵, Marc Lenburg¹⁶, Yi Zhu², Tamara Tchkonia¹⁷, James L Kirkland¹⁸

Affiliations

¹ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Division of Geriatric Medicine and Gerontology, Department of Medicine, Mayo Clinic, Rochester, MN, United States; Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
² Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States.
³ Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
⁴ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Department of Medicine Clinical Trials Unit, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
⁵ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
⁶ Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
⁷ Department of Surgery, Mayo Clinic, Rochester, MN, United States.
⁸ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
⁹ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States.
¹⁰ Division of Hospital Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
¹¹ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States; Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, United States.
¹² Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Office of Research Regulatory Support, Mayo Clinic, Rochester, MN, United States.
¹³ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Division of Geriatric Medicine and Gerontology, Department of Medicine, Mayo Clinic, Rochester, MN, United States; Division of Endocrinology, Department of Medicine, Mayo Clinic, Rochester, MN, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States; Division of Hospital Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
¹⁴ Department of Epidemiology and Biostatistics, School of Public Health, Indiana University - Bloomington, Bloomington, IN, United States.
¹⁵ Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
¹⁶ Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA, United States.
¹⁷ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States. Electronic address: tchkonia.tamar@mayo.edu.
¹⁸ Cellular Senescence and Translation and Pharmacology Programs, Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States; Division of Geriatric Medicine and Gerontology, Department of Medicine, Mayo Clinic, Rochester, MN, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, United States; Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, United States. Electronic address: kirkland.james@mayo.edu.

No abstract available

Publication types

Published Erratum

Publication types

Grants and funding